Key facts
- This page summarizes Michael R. McDonnell's Form 4 filing for BIOGEN INC. (BIIB).
- 7 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 21 Feb 2024, 21:29.
Michael R. McDonnell - 16 Feb 2024 Form 4 Insider Report for BIOGEN INC. (BIIB)
- Reporting relationship
- EVP, Chief Financial Officer
- Issuer ticker
- BIIB
- Reported as of
- 16 Feb 2024
- Net transaction value
- -$753,197
- SEC form
- 4
- Accepted by SEC
- 21 Feb 2024, 21:29:48 UTC
- Prior SEC filing
- 13 Feb 2024
- Next SEC filing
- 20 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Wendell Taylor, attorney-in-fact for Michael R. McDonnell
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael R. McDonnell filed Form 4 for BIOGEN INC. (BIIB) on 21 Feb 2024.
Change
- Previous filing in this sequence was filed on 13 Feb 2024.
- Current net transaction value: -$753,197.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BIIB
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +4,568
- Change %
- +28%
- Price
- $0.000000
- Shares after
- 20,692
- Date
- 16 Feb 2024
- Ownership
- Direct
BIIB
transaction
Common Stock
Tax liability
- Transaction value
- $511,990
- Shares
- -2,337
- Change %
- -11%
- Price
- $219.08
- Shares after
- 18,355
- Date
- 16 Feb 2024
- Ownership
- Direct
BIIB
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +2,152
- Change %
- +12%
- Price
- $0.000000
- Shares after
- 20,507
- Date
- 16 Feb 2024
- Ownership
- Direct
BIIB
transaction
Common Stock
Tax liability
- Transaction value
- $241,207
- Shares
- -1,101
- Change %
- -5.4%
- Price
- $219.08
- Shares after
- 19,406
- Date
- 16 Feb 2024
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BIIB
transaction
Derivative
Performance Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -4,568
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 16 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,568
- Exercise price
- $0.000000
BIIB
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -2,152
- Change %
- -44%
- Price
- $0.000000
- Shares after
- 2,684
- Date
- 16 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,152
- Exercise price
- $0.000000
- Footnotes
- F1
BIIB
transaction
Derivative
Restricted Stock Unit
Other
- Transaction value
- $0
- Shares
- -2,684
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 16 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,684
- Exercise price
- $0.000000
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).
Footnote F2
This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.